TACACICLIB, AUR-102, AURIGENE
New Drug Approvals
JANUARY 9, 2024
The present invention is directed to methods of preparation of compound of formula (I) that is useful for inhibiting Cyclin-dependent kinase 7 (CDK7) and for treating diseases or disorders mediated thereby. Recent genetic and biochemical studies have confirmed the importance of CDK7 for cell cycle progression (Larochelle.
Let's personalize your content